Award
National Cancer Institute 5R01CA275967-04
Pharmacokinetic / Pharmacodynamic Optimization of ADC Therapy for Acute Myeloid Leukemia
Recipient
National Cancer Institute (NCI), part of the NIH
Award Amount
$428,904.00
Ceiling
$428,904.00
Awarded
January 14, 2026
Identifier
5R01CA275967-04
Award for research to optimize ADC therapy for acute myeloid leukemia through PK/PD modeling and antibody development.
Description
This project focuses on developing new strategies to improve the safety and efficacy of antibody-drug conjugate (ADC) therapy for AML, utilizing mechanistic PK/PD modeling, generating new monoclonal antibodies and nanobodies, and evaluating various constructs in mouse models and AML patients.